These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34590580)

  • 41. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncogenic
    Boutin AT; Liao WT; Wang M; Hwang SS; Karpinets TV; Cheung H; Chu GC; Jiang S; Hu J; Chang K; Vilar E; Song X; Zhang J; Kopetz S; Futreal A; Wang YA; Kwong LN; DePinho RA
    Genes Dev; 2017 Feb; 31(4):370-382. PubMed ID: 28289141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway.
    Li X; Deng SJ; Zhu S; Jin Y; Cui SP; Chen JY; Xiang C; Li QY; He C; Zhao SF; Chen HY; Niu Y; Liu Y; Deng SC; Wang CY; Zhao G
    Oncotarget; 2016 Feb; 7(5):6000-14. PubMed ID: 26755660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
    Ferro R; Falasca M
    World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells.
    Sun Y; Zhang Z; Xiang F; Zhang M; Chen Q; Tang L; Zhu L; Liu J; Meng Z; Hu J; Luo X; Ni Z; Wang X
    Life Sci; 2020 Apr; 246():117428. PubMed ID: 32057901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Arl4c is a key regulator of tubulogenesis and tumourigenesis as a target gene of Wnt-β-catenin and growth factor-Ras signalling.
    Matsumoto S; Fujii S; Kikuchi A
    J Biochem; 2017 Jan; 161(1):27-35. PubMed ID: 28053143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer.
    Kanai R; Uehara T; Yoshizawa T; Kamakura M; Nakajima T; Kinugawa Y; Iwaya M; Asaka S; Kitazawa M; Nagaya T; Ota H
    BMC Cancer; 2023 May; 23(1):478. PubMed ID: 37237373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
    Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
    Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice.
    Görgülü K; Diakopoulos KN; Ai J; Schoeps B; Kabacaoglu D; Karpathaki AF; Ciecielski KJ; Kaya-Aksoy E; Ruess DA; Berninger A; Kowalska M; Stevanovic M; Wörmann SM; Wartmann T; Zhao Y; Halangk W; Voronina S; Tepikin A; Schlitter AM; Steiger K; Artati A; Adamski J; Aichler M; Walch A; Jastroch M; Hartleben G; Mantzoros CS; Weichert W; Schmid RM; Herzig S; Krüger A; Sainz B; Lesina M; Algül H
    Gastroenterology; 2019 Jan; 156(1):203-217.e20. PubMed ID: 30296435
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
    Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
    Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
    Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL
    Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
    Zhu Z; Xiao S; Hao H; Hou Q; Fu X
    Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy.
    Pattanayak R; Barua A; Das A; Chatterjee T; Pathak A; Choudhury P; Sen S; Saha P; Bhattacharyya M
    Eur J Pharm Sci; 2018 Dec; 125():39-53. PubMed ID: 30223034
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis.
    Sivakumar S; de Santiago I; Chlon L; Markowetz F
    PLoS Med; 2017 Jan; 14(1):e1002223. PubMed ID: 28141826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation.
    Mills LD; Zhang Y; Marler RJ; Herreros-Villanueva M; Zhang L; Almada LL; Couch F; Wetmore C; Pasca di Magliano M; Fernandez-Zapico ME
    J Biol Chem; 2013 Apr; 288(17):11786-94. PubMed ID: 23482563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.